Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04480567
PHASE1/PHASE2

AAV Gene Therapy Study for Subjects with PKU

Sponsor: BioMarin Pharmaceutical

View on ClinicalTrials.gov

Summary

This is a Phase 1/2, open-label, dose escalation study to evaluate the safety, efficacy and tolerability of BMN 307 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of BMN 307 and will be followed for safety and efficacy.

Official title: A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria

Key Details

Gender

All

Age Range

15 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2020-09-24

Completion Date

2027-12

Last Updated

2024-12-12

Healthy Volunteers

No

Interventions

DRUG

BMN 307

AAV Gene Therapy Infusion

Locations (3)

University of South Florida

Tampa, Florida, United States

Morristown Medical Center

Morristown, New Jersey, United States

University Hospital Birmingham NHS Foundation Trust

Birmingham, United Kingdom